PHAT Q3 2025 Earnings — Phathom Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

PHATPhathom Pharmaceuticals, Inc.

$891M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+202.7% YoY

Gross Profit

$43M87.5% margin

Operating Income

-$15M-30.8% margin

Net Income

-$30M-60.5% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+25.3%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$240M

Total Liabilities

$663M

Stockholders' Equity

-$423M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$16M	+202.7%
Gross Profit	$43M	$14M	+209.5%
Operating Income	-$15M	-$71M	+78.4%
Net Income	-$30M	-$86M	+65.0%